title: Evidence for the role of hindbrain orexin-1 receptors in the control of meal size.
abstract: Hypothalamic orexin neurons project to the hindbrain, and 4th-ventricle intracerebroventricular (4th-icv) injection of orexin-A treatment increases food intake. We assessed the effects of hindbrain orexin-A and the orexin-1-receptor antagonist SB334867 on meal pattern in rats consuming standard chow. When injected 4th-icv shortly before dark onset, lower doses of orexin-A increased food intake over a 2-h period by increasing the size of the first meal relative to vehicle, whereas the highest dose increased food intake by causing the second meal to be taken sooner. Conversely, hindbrain SB334867 reduced food intake by decreasing the size of the first meal of the dark phase. We also examined the effects of 4th-icv orexin-A and SB334867 on locomotor activity. Only the highest dose of orexin-A increased activity, and SB334867 had no effect. In addition, hindbrain SB334867 induced c-Fos in the nucleus of the solitary tract. These data support the suggestion that endogenous hindbrain orexin-A acts to limit satiation. Both orexin-A and the pancreatic satiation hormone amylin require an intact area postrema to affect food intake, so we asked whether 4th-icv orexin-A impairs the satiating effect of peripheral amylin treatment. Amylin reduced the size of the first meal of the dark cycle when rats were pretreated with 4th-icv saline, yet amylin was ineffective after 4th-icv orexin-A pretreatment. Using double-label immunohistochemistry, we determined that some orexin-A fibers in the area postrema are located in proximity to amylin-responsive neurons. Therefore, hindbrain orexin-A may increase food intake, in part, by reducing the ability of rats to respond to amylin during a meal.
authors.affiliation: Department of Psychology and Program in Neuroscience, Florida State University, Tallahassee, Florida 32306-4301, USA.
authors.forename: Eric M
authors.initials: EM
authors.lastname: Parise
authors.forename: Nicole
authors.initials: N
authors.lastname: Lilly
authors.forename: Kristen
authors.initials: K
authors.lastname: Kay
authors.forename: Amanda M
authors.initials: AM
authors.lastname: Dossat
authors.forename: Rohit
authors.initials: R
authors.lastname: Seth
authors.forename: J Michael
authors.initials: JM
authors.lastname: Overton
authors.forename: Diana L
authors.initials: DL
authors.lastname: Williams
mesh_terms: D000818:Animals; D001583:Benzoxazoles / Q000494:pharmacology*; D004435:Eating / Q000187:drug effects / Q000502:physiology*; D047908:Intracellular Signaling Peptides and Proteins / Q000494:pharmacology*; D058228:Islet Amyloid Polypeptide / Q000494:pharmacology; D008297:Male; D009043:Motor Activity; D009287:Naphthyridines; D009479:Neuropeptides / Q000494:pharmacology*; D064446:Orexin Receptors; D000068797:Orexins; D017440:Photoperiod; D051381:Rats; D017208:Rats, Wistar; D043562:Receptors, G-Protein-Coupled / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D018013:Receptors, Neuropeptide / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D012249:Rhombencephalon / Q000378:metabolism*; D012527:Satiation / Q000187:drug effects / Q000502:physiology; D014508:Urea / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: C420062:1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea; D001583:Benzoxazoles; D047908:Intracellular Signaling Peptides and Proteins; D058228:Islet Amyloid Polypeptide; D009287:Naphthyridines; D009479:Neuropeptides; D064446:Orexin Receptors; D000068797:Orexins; D043562:Receptors, G-Protein-Coupled; D018013:Receptors, Neuropeptide; D014508:Urea